Back to search results

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Abroad (travel likely)RecruitingPHASE1

Conditions

Renal Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Stephanie Berg) · 617-632-4932

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Martin Voss) · 646-888-4721

  • Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Elizabeth Plimack) · 215-728-3889

  • SCRI Oncology Partners, Nashville, Tennessee, United States

    Contact: Study coordinator (Benjamin Garmezy) · 713-444-7804

  • START San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Amita Patnaik) · 210-593-5250

  • Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada

    Contact: Study coordinator (Daniel Heng) · 4035213166

  • Gustave Roussy, Villejuif, Val-de-Marne, France

    Contact: Study coordinator (Christophe Massard) · +33142114211

  • Hospital Universitario Reina Sofia, Córdoba, Andalusia, Spain

    Contact: Study coordinator (MARIA JOSE MENDEZ VIDAL) · +34957011448

  • Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain

    Contact: Study coordinator (Cristina Suarez Rodriguez) · 349327460004350
Study leads

  • Bristol-Myers Squibb

    Study Director

    Bristol-Myers Squibb

View source on ClinicalTrials.gov(opens in a new tab)